Skip to content

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Library

By pinki shah / May 14, 2022

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 2,201 - 2,225 of 2,711

«
1
…
87
88
89
90
91
…
109
»

PIK3CA/AKT/mTOR

PIK3CA/AKT/mTOR

By: Jacob Thomas, MD

PIK3CA/AKT/mTOR

PIK3CA/AKT/mTOR

By: Jacob Thomas, MD

Targeting RAS-RAF-MAPK Pathway

Targeting RAS-RAF-MAPK Pathway

By: Jacob Thomas, MD

Hippo-Yap Pathway

Hippo-Yap Pathway

By: Janai Carr-Ascher, MD, PhD

DDR and DNA-Repair Pathways and Targets

DDR and DNA-Repair Pathways and Targets

By: Mamta Parikh, MD, MS

DDR and DNA-Repair Pathways and Targets

DDR and DNA-Repair Pathways and Targets

By: Mamta Parikh, MD, MS

By: Mille Das, MD

By: Mille Das, MD

Novel Targets: HER-2, NRG1, TROP2, CEACAM5 & HER-3

Novel Targets: HER-2, NRG1, TROP2, CEACAM5 & HER-3

By: Rebecca Heist, MD, MPH

Novel Targets: HER-2, NRG1, TROP2, CEACAM5 & HER-3

Novel Targets: HER-2, NRG1, TROP2, CEACAM5 & HER-3

By: Rebecca Heist, MD, MPH

Innovative Early Phase Clinical Trial Designs

Innovative Early Phase Clinical Trial Designs

By: Shivaani Kummar - MD - FACP

Immune Checkpoint Inhibitors in Cancer Patients with Autoimmune Disease

Immune Checkpoint Inhibitors in Cancer Patients with Autoimmune Disease

By: Shivaani Kummar, MD

Targeting the Microbiome and Optimizing Immunotherapy in Cancer

Targeting the Microbiome and Optimizing Immunotherapy in Cancer

By: Sumanta K. Pal, MD, FASCO

Legislation & Reimbursement

Legislation & Reimbursement

By: Ted Okon, MBA

BTK inhibitors, BCL-2 Inhibitors and Novel Targets in Hematology

BTK inhibitors, BCL-2 Inhibitors and Novel Targets in Hematology

By: Tycel Phillips, MD

BTK inhibitors, BCL-2 Inhibitors and Novel Targets in Hematology

BTK inhibitors, BCL-2 Inhibitors and Novel Targets in Hematology

By: Tycel Phillips, MD

Novel Targets in Hematologic Malignancies

Novel Targets in Hematologic Malignancies

By: Tycel Phillips, MD

Precision Medicine in an Era of Value Based Medicine

Precision Medicine in an Era of Value Based Medicine

By: Vincent Chung, MD, FACP

The New Face of Oral Cancer

The New Face of Oral Cancer

By: Robert E Marx, DDS

The New Osteonecrosis Of The Jaws

The New Osteonecrosis Of The Jaws

By: Robert E. Marx, DDS

Management of Osteonecrosis of Jaw and Other Complications from Bisphosphonate and/or RANK Ligand Inhibitors

Management of Osteonecrosis of Jaw and Other Complications from Bisphosphonate and/or RANK Ligand Inhibitors

By: Robert E. Marx, DDS, FACS

Management of Osteonecrosis of Jaw and Other Complications from Bisphosphonate and/or RANK Ligand Inhibitors

Management of Osteonecrosis of Jaw and Other Complications from Bisphosphonate and/or RANK Ligand Inhibitors

By: Robert E. Marx, DDS, FACS

The Future of Anesthesia in OMFS: The Outlook

The Future of Anesthesia in OMFS: The Outlook

By: Andrew D. Stiles, DDS

The Future of Anesthesia in OMFS: The Outlook

The Future of Anesthesia in OMFS: The Outlook

By: Andrew D. Stiles, DDS

RANKL Inhibitors and DIONJ

RANKL Inhibitors and DIONJ

By: Andrew Sugar, DDS

«
1
…
87
88
89
90
91
…
109
»

Post navigation

← Previous View

© 2024 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok